Company Overview

Clene Inc. is a U.S.-based clinical-stage biopharmaceutical company focused on developing novel therapeutics for neurodegenerative diseases. The company operates within the biotechnology and pharmaceutical research industry, with a primary emphasis on central nervous system (CNS) disorders. Its core strategy is centered on restoring neuronal health and function by improving cellular bioenergetics and reducing neurodegeneration rather than targeting disease-specific symptoms alone.

The company’s primary product candidate is CNM-Au8, an oral suspension of catalytically active gold nanocrystals designed to enhance cellular energy metabolism and promote neuronal survival. Clene’s lead clinical focus includes amyotrophic lateral sclerosis (ALS), multiple sclerosis (MS), and Parkinson’s disease. Clene was founded in 2013 and evolved from early-stage nanotechnology research into a publicly traded clinical-stage biotechnology company, completing its public listing through a merger transaction in 2021.

Business Operations

Clene operates as a single-reportable segment focused on pharmaceutical research and development. Its business activities are concentrated on advancing CNM-Au8 through clinical trials, regulatory engagement, and potential commercialization. The company does not currently generate product revenue and relies primarily on equity financing, grants, and public offerings to fund operations, consistent with other clinical-stage biotechnology companies.

The company controls proprietary nanotechnology platforms related to gold nanocrystal catalysis and drug formulation. Research and development activities are conducted through a combination of internal scientific teams and third-party clinical research organizations. Clene’s wholly owned subsidiary, Clene Nanomedicine, Inc., conducts the majority of the company’s R&D and clinical operations. Data inconclusive based on available public sources regarding any material joint ventures or revenue-generating partnerships.

Strategic Position & Investments

Clene’s strategic direction focuses on advancing CNM-Au8 through late-stage clinical development and pursuing regulatory pathways for neurodegenerative indications with high unmet medical need. Growth initiatives include expanding clinical trial programs, pursuing biomarker-driven validation of therapeutic effects, and seeking non-dilutive funding through grants and collaborations.

The company has made strategic investments in intellectual property related to nanocrystal-based catalytic medicine and holds a portfolio of issued and pending patents supporting its technology platform. Clene has not disclosed any material acquisitions of commercial-stage companies. Its emerging technology focus lies at the intersection of nanomedicine, mitochondrial biology, and neuroprotection, positioning it distinctively within the neurodegenerative disease treatment landscape.

Geographic Footprint

Clene is headquartered in the United States, with its principal executive offices located in Utah. Its operations are primarily U.S.-based, including management, research oversight, and regulatory activities. Clinical trials sponsored by the company have included investigational sites across North America and select international locations, depending on study design and regulatory approvals.

While Clene does not maintain significant commercial operations outside the U.S., its clinical and scientific activities have an international reach through global trial participation and engagement with international regulatory authorities. Data inconclusive based on available public sources regarding permanent operational facilities outside the United States.

Leadership & Governance

Clene is led by an executive team with backgrounds in biotechnology, clinical development, and corporate leadership, guided by a strategy focused on scientific rigor, regulatory alignment, and long-term value creation for patients and shareholders.

Key executives include:

• Rob Etherington – President and Chief Executive Officer
• Dr. Robert Glanzman – Chief Medical Officer
• Morgan Brown – Chief Financial Officer
• Dr. Michael Hotchkiss – Chief Scientific Officer

The leadership team emphasizes a science-driven development philosophy, prioritizing clinical evidence, biomarker validation, and disciplined capital allocation. Governance is overseen by a board of directors with experience in life sciences, finance, and public company oversight.